Jeffrey H. Price
Principal investigator.
Medtech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2021First federal award
$4.5MFederal grants as PI11 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
11 awards · $4.5M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Aug 6, 2025 | NIH | SBIR Phase II Neural Circuits, Kinetics and Energetics HTS of Human iPSC-Neurons, -Microglia, and -Astrocytes: AI-Enabled Platform for Target ID, and Drug Discovery and Toxicity (e.g., Cancer Chemo & HIV ARTs) | $1.1M | VALA SCIENCES, INC. |
| Aug 28, 2024 | NIH | SBIR Phase II Neural Circuits, Kinetics and Energetics HTS of Human iPSC-Neurons, -Microglia, and -Astrocytes: AI-Enabled Platform for Target ID, and Drug Discovery and Toxicity (e.g., Cancer Chemo & HIV ARTs) | $1.1M | VALA SCIENCES, INC. |
| Aug 15, 2024 | NIH | STTR Phase II Combined Cardiomyopathy, e.g., of Cancer Chemotherapeutics, and Proarrhythmia for Cardiotoxicity Clinical Trials-in-a-Dish (CTiD) with iPSC-Derived Cardiomyocytes | $153K | VALA SCIENCES, INC. |
| Aug 12, 2024 | NIH | STTR Phase II Combined Cardiomyopathy, e.g., of Cancer Chemotherapeutics, and Proarrhythmia for Cardiotoxicity Clinical Trials-in-a-Dish (CTiD) with iPSC-Derived Cardiomyocytes | $14K | VALA SCIENCES, INC. |
| Aug 9, 2024 | NIH | STTR Phase II Combined Cardiomyopathy, e.g., of Cancer Chemotherapeutics, and Proarrhythmia for Cardiotoxicity Clinical Trials-in-a-Dish (CTiD) with iPSC-Derived Cardiomyocytes | $174K | VALA SCIENCES, INC. |
| Aug 7, 2024 | NIH | STTR Phase II Combined Cardiomyopathy, e.g., of Cancer Chemotherapeutics, and Proarrhythmia for Cardiotoxicity Clinical Trials-in-a-Dish (CTiD) with iPSC-Derived Cardiomyocytes | $920K | VALA SCIENCES, INC. |
| Jun 27, 2024 | NIH | STTR Phase II Combined Cardiomyopathy, e.g., of Cancer Chemotherapeutics, and Proarrhythmia for Cardiotoxicity Clinical Trials-in-a-Dish (CTiD) with iPSC-Derived Cardiomyocytes | $10K | VALA SCIENCES, INC. |
| Jun 12, 2024 | NIH | STTR Phase II Combined Cardiomyopathy, e.g., of Cancer Chemotherapeutics, and Proarrhythmia for Cardiotoxicity Clinical Trials-in-a-Dish (CTiD) with iPSC-Derived Cardiomyocytes | $17K | VALA SCIENCES, INC. |
| Jan 22, 2024 | NIH | STTR Phase II Combined Cardiomyopathy, e.g., of Cancer Chemotherapeutics, and Proarrhythmia for Cardiotoxicity Clinical Trials-in-a-Dish (CTiD) with iPSC-Derived Cardiomyocytes | $120K | VALA SCIENCES, INC. |
| Sep 1, 2023 | NIH | SBIR Phase II Neural Circuits, Kinetics and Energetics HTS of Human iPSC-Neurons, -Microglia, and -Astrocytes: AI-Enabled Platform for Target ID, and Drug Discovery and Toxicity (e.g., Cancer Chemo & HIV ARTs) | $566K | VALA SCIENCES, INC. |
| May 26, 2021 | NIH | STTR Phase II Combined Cardiomyopathy, e.g., of Cancer Chemotherapeutics, and Proarrhythmia for Cardiotoxicity Clinical Trials-in-a-Dish (CTiD) with iPSC-Derived Cardiomyocytes | $300K | VALA SCIENCES, INC. |
Peer ranks
Federal funding#347
Awards as PI#114
Patents#505
Companies
- VALA SCIENCES, INC.Linked by awards · Medtech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.